Small molecule · Cytotoxic, directed at DNA · developed by Alaunos Therapeutics
Palifosfamide is a synthetic mustard compound and stabilized active metabolite of ifosfamide that irreversibly alkylates and crosslinks DNA through GC base pairs, causing interstrand crosslinks and inhibiting DNA replication. It is studied in advanced sarcoma, soft tissue sarcoma, small cell lung cancer, and metastatic breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01555710 | Phase 3 | Extensive-Stage Small Cell Lung Cancer | Terminated | TCRT |
| NCT01168791 | Phase 3 | Soft Tissue Sarcoma | Terminated | TCRT |
| NCT01703754 | Phase 2 | Breast Cancer Nos Metastatic Recurrent | Terminated | TCRT |
| NCT00718484 | Phase 2 | Soft Tissue Sarcoma | Terminated | TCRT |
| NCT00439686 | Phase 1/2 | Advanced Sarcoma | Completed | TCRT |
| NCT00607711 | Phase 1 | Advanced Cancer | Withdrawn | TCRT |
| NCT00608803 | Phase 1 | Advanced Cancer | Completed | TCRT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced CancerAdvanced SarcomaBreast Cancer Nos Metastatic RecurrentExtensive-Stage Small Cell Lung CancerSoft Tissue Sarcoma
Updated Oct 3, 2026. Something wrong or missing? Report it on the TCRT page.
See TCRT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TCRT catalysts and pipeline →